A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 257 participants.

Also called NCT05691712

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 257 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05691712
Other papers using this trial's data
  • Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial The lancet. Diabetes & endocrinology, 2025-12 DOI, PubMed 41167231

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05691712. Randomized; double masking; primary purpose treatment. Start 2023-02-05 (actual); primary completion 2024-07-01 (actual). Results posted on 2025-08-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
Acronym
SURPASS-CN-INS
Condition
Diabetes Type 2
Condition
Diabetes Mellitus
Condition
Glucose Metabolism Disorders
Condition
Metabolic Disease
Condition
Endocrine System Diseases
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05691712
Content hash
f13a2beca3bb655d698a2b992d6341c3514e3f4c08add8b8d2c809c0d83a3dd5